ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Tamas Kullmann, Annick Ankri, Marc-Olivier Bitker, Serge Herson, Olivier Benveniste
The case of a forty-five year old woman is presented who consulted for spontaneous haematomas of the thighs. The diagnosis of acquired haemophilia A associated to renal cancer was retained. She received anti CD<sub>20</sub> monoclonal antibody treatment allow…
Shahnaz Khaghani, Farideh Razi, Mohsen Mohammadian Yajloo, Malihe Paknejad, Ahmad Shariftabrizi, Parvin Pasalar
Background: Herbal compounds are attractive anticancer candidates due to their low toxicity. Pervious studies have demonstrated that Hibiscus sabdariffa is promising as an anticancer agent against several cancer types; however, its potential therapeutic role…
Yu-Quan Wu, Jun Yang, Xi-Jian Zhou, Peng Li, Xiao-Qiang Fan, Guang-Zhou Lu, Yan-Juan Pan, Xiang-Yong Li, Fu-Lin Yan
The standard chemotherapy for Chinese elderly patients with non-small cell lung cancer (NSCLC) remains undefined. The study was to evaluate the therapeutic effects as well as side effects of pemetrexed plus carboplatin regimen as the first-line therapy for Ch…
Alfonso Sánchez-Muñoz, Nuria Ribelles, Emilio Alba
Purpose: Several studies have reported a positive impact for taxanes in adjuvant breast cancer (BC) treatment in terms of reduced recurrence and mortality. However the impact of the magnitude on overall survival (OS) remains partially controversial. Methods:…
Stanislaw R. Burzynski, Alejandro Marquis, Eva Nagy-Kubove, Tomasz Janicki
We present an interesting case of a 56-year-old female diagnosed with invasive high-grade triple-negative breast cancer, who developed diffuse liver metastases following lumpectomy and combination chemotherapy with docetaxel, doxorubicin and cyclophosphamide,…
Didier Dequanter, Delphine Geukens, Jean-Marie Bailly, Mohammad Shahla, Pascal Paulus, Philippe Lothaire
Objectives: Elective neck treatment of clinically N0 patients in patients with head and neck carcinomas is widely accepted as a standard approach. However, the issue whether elective neck treatment should routinely be directed on both sides of the neck is sti…
Vinod Prabhu, Siddik Uzzaman, Viswanathan Mariammal Berlin Grace, Chandrasekharan Guruvayoorappan
Nanotechnology has the potential to offer solutions to these current obstacles in cancer therapies, because of its unique size and large surface-to-volume ratios. Nanoparticles may have properties of self-assembly, stability, specificity, drug encapsulation a…
James Chen, Peter S. Edelstein, Philip J. Johnson, Robert Lustig, Lucien Ooi
Despite the development of new targeted cancer therapies, primary and secondary tumors continue to be a leading cause of suffering and mortality worldwide. The complexity and heterogeneity of malignancies ultimately result in tumor resistance to therapies, su…
Renee N. Donahue, Ian S. Zagon, Patricia J. McLaughlin
Ovarian cancer is the 5th leading cause of cancer-related mortality in women. Seventy-five percent of ovarian cancer patients present in advanced stages, and receive cytoreductive surgery and adjuvant chemotherapy. However, within 2 years 65% of these patient…
Erin Bard, Wei Hu
Personalized medicine is critical for lung cancer treatment. Different gene signatures that can classify lung cancer patients as high- or low-risk for cancer recurrence have been found. The aim of this study is to identify a novel gene signature that has high…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).